Seasonal Allergic RhinitisPhase 2NCT06760182
Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis
A Phase 2 study testing TQH2722 injection in people with Seasonal Allergic Rhinitis, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. at 30 sites in China.
Trial summary
To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Seasonal Allergic Rhinitis
- What is being tested?
- TQH2722 injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 169 participants
- Where
- 30 sitesChina
- Study dates
- 10 Mar 2025to 1 Jul 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 to 75 years at the screening period.
- Patients who met the diagnostic criteria of allergic rhinitis in Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition, 2022)
- Positive of at least 1 allergen skin prick test(SPT) and/or serum-specific IgE within 1 year before enrollment.
- Subjects have sufficient pollen exposure during the pollen season:
- Subjects' medical history suggested that SAR symptoms were poorly controlled or subjects' subjective symptoms were not satisfactorily controlled after drug treatment during the same pollen season in the past.
- On the day of screening, the iTNSS score in the morning was ≥4; At baseline visit, the morning iTNSS was ≥4 points, and the average score of the past 6 rTNSS was ≥6 points;
Show all 11Show fewer
- At baseline visit, the absolute value of peripheral blood eosinophils was ≥0.15×109/L;
- During the screening/induction period, the subjects had good compliance;
- Subjects with asthma who were assessed by the investigator or specialist as having stable asthma;
- Voluntary participation in this trial and signing the informed consent form
- Subjects (including partners) have no pregnancy and voluntarily take one or more non-pharmaceutical measures for contraception at period from drug administration to 6 months after the last study drug administration
Who cannot join
- Laboratory test values did not meet the requirements during screening or randomization
- Any disease that the investigator believes interferes with the patient's ability to complete the entire course of the study;
- Patients with active autoimmune disease
- People with known or suspected immunosuppression
- Subjects with active malignancy or a history of malignancy;
- Active hepatitis or hepatitis B was present during the screening period; Or human immunodeficiency virus antibody (Anti-HIV) positive, or treponema pallidum antibody (Anti-TP) positive;
Show all 17Show fewer
- Diagnosis of helminthic infection within 6 months prior to screening, not receiving standard treatment or not responding to standard treatment;
- Subjects who have undergone nasal surgery or sinus surgery within 6 months before screening
- Subjects have concomitant medical conditions that preclude them from completing the screening period assessment or evaluating the primary efficacy endpoint;
- Subjects with nasal malignancies and benign tumors;
- History of hypersensitivity to any content of the study drugs or its excipients
- Subjects with a history of systemic allergy to any biological agent;
- Pregnant or lactating women;
- Alcohol, drug and known drug dependence;
- Have a history of vital organ transplantation or hematopoietic stem cell/bone marrow transplantation;
- Any medical or psychiatric condition that, in the investigator's judgment, puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results;
- Any condition that the investigator or primary physician believes may not be appropriate for participating the study
Trial locations and contacts
30 sites in 1 country.
30 sites in 1 country
China30 sites
Ansteel Group General hospital
Anshan, Liaoning, 114000
Baotou Central Hospital
Baotou, Inner Mongolia, 014000
Peking University First Hospital
Beijing, Beijing Municipality, 100034
Peking University People's Hospital
Beijing, Beijing Municipality, 100044
Peking University Third Hospital
Beijing, Beijing Municipality, 100191
Cangzhou Central Hospital
Cangzhou, Hebei, 061017
Chifeng Municipal Hospital
Chifeng, Inner Mongolia, 024005
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, 015000
Shandong Second Provincial General Hospital
Jinan, Shandong, 250000
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650032
Gansu Provincial Hospital
Lanzhou, Gansu, 730000
Qilu Hospital of Shandong University
Qilu, Shandong, 250012
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004
Hebei Medical University Third Hospital
Shijiazhuang, Hebei, 50000
Shanxi Bethune Hospital
Taiyuan, Shanxi, 030000
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300041
Tianjin People's Hospital
Tianjin, Tianjin Municipality, 300121
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, 300192
Liaoning Health Industry Group Iron Coal General Hospital
Tieling, Liaoning, 112700
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830054
The Central Hospital of Wuhan
Wuhan, Hubei, 430014
Union Hospital, Tongji Medical College, Huazhong University of science and technology
Wuhan, Hubei, 430022
Tongji Hospital of Tongji medical college of HUST
Wuhan, Hubei, 430030
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710004
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000
The First People's Hospital of Yinchuan
Yinchuan, Ningxia, 750000
Henan Provincial People's Hospital
Zhengzhou, Henan, 450000
Zibo Central Hospital
Zibo, Shandong, 255036
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH2722 Injection Combined With Background Therapy in Patients With Seasonal Allergic Rhinitis
To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal allergic rhinitis (SAR) who have failed to respond to standard treatments.
- Conditions
- Seasonal Allergic Rhinitis
- Being tested
- TQH2722 injection, TQH2722 Placebo
- Medical subject headings
- Rhinitis, Allergic, Seasonal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TQH2722 injectionDrug
TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
TQH2722 PlaceboDrug
Placebo without drug substance.
| Study group | Role | What they receive |
|---|---|---|
| TQH2722 injection | Experimental | Not described Receives: Drug: TQH2722 injection |
| TQH2722 Placebo | Placebo comparator | TQH2722 placebo, 1 weeks as a treatment cycle. Receives: Drug: TQH2722 Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Retrospective nasal symptom score after treatment for 2 weeks
Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 2 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 weeks
Secondary outcomes (25)
Retrospective nasal symptom score after treatment for 4 weeks
Mean daily retrospective nasal symptom total score (rTNSS) changes from baseline at 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 4 weeks
Mean daily changes in retrospective nasal symptom total score
Mean daily changes in retrospective nasal symptom total score (AM rTNSS) from baseline at 2 weeks and 4 weeks after treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Mean daily nightly retrospective nasal symptom total score
Mean daily nightly retrospective nasal symptom total score (PM rTNSS) changes from baseline at 2 weeks and 4 weeks after treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean change of instantaneous nasal symptom total score (iTNSS) from baseline
Mean change of instantaneous nasal symptom total score (iTNSS) from baseline every morning before treatment for 2 weeks and 4 weeks. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean daily rTNSS change from baseline
Mean daily rTNSSchange from baseline at 2 weeks and 4 weeks of treatment; The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean change rate of iTNSS from baseline
Mean change rate of iTNSS from baseline before treatment at 2 weeks and 4 weeks each morning. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in daily retrospective nasal symptom scores
Mean changes from baseline in daily retrospective nasal symptom scores (runny nose, nasal congestion, nasal itchy, and sneezing) at 2 and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in scores of individual nasal symptoms during the day
Mean changes from baseline in scores of individual nasal symptoms (runny nose, nasal congestion, itchy nose, and sneezing) were reviewed daily (AM) at 2 weeks and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in scores of individual nasal symptoms at night
Mean changes from baseline in scores of individual nasal symptoms (runny nose, nasal congestion, nasal itchy and sneezing) at night (PM) after 2 and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean changes in daily retrospective ocular symptom score
Mean changes in daily retrospective ocular symptom score (rTOSS) from baseline at 2 and 4 weeks of treatment; The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean changes in retrospective ocular symptom score during the day
Mean daily changes in retrospective ocular symptom score (AM rTOSS) from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean retrospective ocular symptom score at night
Mean nightly retrospective ocular symptom score (PM rTOSS) changes from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean change of instantaneous ocular symptom total score
Mean change of instantaneous ocular symptom total score (iTOSS) from baseline every morning at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean rate of change in daily rTOSS
Mean rate of change in daily rTOSS from baseline at 2 and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Retrospective nasal symptom score: Average daily retrospective nasal symptom score
Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 4 weeks of treatment. The total score is 0-12points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 4 weeks
Retrospective ocular symptom score: Mean change rate of iTOSS each morning
Mean change rate of iTOSS from baseline before treatment at 2 weeks and 4 weeks each morning. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes in scores of individual ocular symptoms
Average changes in scores of individual ocular symptoms (itchy, tearing, red eyes) at 2 and 4 weeks of treatment compared with baseline. The single score is 0-3 points, with the higher score meaning the more severe symptoms
Measured: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes of individual ocular symptom scores during the day
Average changes of individual ocular symptom scores (itchy, watery eyes, red eyes) compared with baseline were reviewed daily (AM) at 2 weeks and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes of individual ocular symptoms at night
Average changes of individual ocular symptoms (itchy, watery eyes, red eyes) scores at night (PM) after 2 weeks of treatment and 4 weeks of treatment compared with baseline. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Quality of life questionnaire
Changes in quality of life questionnaire (RQLQ) scores from baseline for patients with allergic rhinitis after 2 weeks and 4 weeks of treatment. The total score is 0-168 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Time of onset
Time of onset after treatment.
Measured: Baseline up to 4 weeks
Time to Reach Maximum Plasma Concentration (Tmax)
Time to reach maximum plasma concentration after administration.
Measured: Baseline up to 4 weeks
Area under the curve
Area under the curve of mean daily rTNSS change from baseline at 2 and 4 weeks of treatment
Measured: Baseline up to 2 and 4 weeks
Number of days with no or mild symptoms of Allergic rhinitis symptoms
Number of days with no or mild symptoms during 2 weeks and 4 weeks of treatment
Measured: Baseline up to 2 and 4 weeks
Adverse event rate
Incidence and severity of adverse events (AE) and serious adverse events (SAE), physical examination, vital signs, 12-lead electrocardiogram (ECG), and abnormal laboratory indicators.
Measured: Baseline up to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2025
- Study start10 Mar 2025
- Primary completion30 Apr 2025
- Study completion1 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Seasonal Allergic RhinitisStudies of the same condition, open and under way.
- More trials run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 169 participants (actual)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06760182
- Sponsor's protocol ID
- TQH2722-II-05
- Status last verified
- Oct 2024
- First submitted
- 25 Dec 2024
- Last updated
- 12 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH2722 Injection Combined With Background Therapy in Patients With Seasonal Allergic Rhinitis
- ClinicalTrials.gov ID
- NCT06760182
- Acronym / sponsor ID
- TQH2722-II-05
- Conditions
- Seasonal Allergic Rhinitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 169 participants (actual)
- Lead sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 10 Mar 2025 (actual)
- Primary completion
- 30 Apr 2025 (actual)
- Study completion
- 1 Jul 2025 (actual)
- First posted
- 6 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal allergic rhinitis (SAR) who have failed to respond to standard treatments.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TQH2722 injection | Experimental | Drug: TQH2722 injection |
| TQH2722 Placebo | Placebo comparator | Drug: TQH2722 PlaceboTQH2722 placebo, 1 weeks as a treatment cycle. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Aged 18 to 75 years at the screening period.
- Patients who met the diagnostic criteria of allergic rhinitis in Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition, 2022)
- Positive of at least 1 allergen skin prick test(SPT) and/or serum-specific IgE within 1 year before enrollment.
- Subjects have sufficient pollen exposure during the pollen season:
- Subjects' medical history suggested that SAR symptoms were poorly controlled or subjects' subjective symptoms were not satisfactorily controlled after drug treatment during the same pollen season in the past.
Key exclusion criteria (17 listed)
- Laboratory test values did not meet the requirements during screening or randomization
- Any disease that the investigator believes interferes with the patient's ability to complete the entire course of the study;
- Patients with active autoimmune disease
- People with known or suspected immunosuppression
- Subjects with active malignancy or a history of malignancy;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TQH2722 injectionTQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα). | Drug | TQH2722 injection |
| TQH2722 PlaceboPlacebo without drug substance. | Drug | TQH2722 Placebo |
Primary outcome
Retrospective nasal symptom score after treatment for 2 weeks
Time frame: Baseline up to 2 weeks
Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 2 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
25 secondary outcomes
Retrospective nasal symptom score after treatment for 4 weeks
Time frame: Baseline up to 4 weeks
Mean daily changes in retrospective nasal symptom total score
Time frame: Baseline up to 2 and 4 weeks
Mean daily nightly retrospective nasal symptom total score
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean change of instantaneous nasal symptom total score (iTNSS) from baseline
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean daily rTNSS change from baseline
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean change rate of iTNSS from baseline
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in daily retrospective nasal symptom scores
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in scores of individual nasal symptoms during the day
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in scores of individual nasal symptoms at night
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean changes in daily retrospective ocular symptom score
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean changes in retrospective ocular symptom score during the day
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean retrospective ocular symptom score at night
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean change of instantaneous ocular symptom total score
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean rate of change in daily rTOSS
Time frame: Baseline up to 2 and 4 weeks
Retrospective nasal symptom score: Average daily retrospective nasal symptom score
Time frame: Baseline up to 4 weeks
Retrospective ocular symptom score: Mean change rate of iTOSS each morning
Time frame: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes in scores of individual ocular symptoms
Time frame: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes of individual ocular symptom scores during the day
Time frame: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes of individual ocular symptoms at night
Time frame: Baseline up to 2 and 4 weeks
Quality of life questionnaire
Time frame: Baseline up to 2 and 4 weeks
Time of onset
Time frame: Baseline up to 4 weeks
Time to Reach Maximum Plasma Concentration (Tmax)
Time frame: Baseline up to 4 weeks
Area under the curve
Time frame: Baseline up to 2 and 4 weeks
Number of days with no or mild symptoms of Allergic rhinitis symptoms
Time frame: Baseline up to 2 and 4 weeks
Adverse event rate
Time frame: Baseline up to 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2025.
Related trials for Seasonal Allergic Rhinitis
RecruitingPhase 1
Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy
Birch Pollen Allergy
Active, not recruitingPhase 3
A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Enrolling by invitationObservational study
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
Pollen Allergy
RecruitingObservational study
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
Allergic Rhinoconjunctivitis
Recruiting
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
30 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing TQH2722 injection in people with Seasonal Allergic Rhinitis, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. at 30 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retrospective nasal symptom score after treatment for 2 weeks (time frame: Baseline up to 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2025.